KR102212975B1 - 피리딘-4-일 유도체 - Google Patents

피리딘-4-일 유도체 Download PDF

Info

Publication number
KR102212975B1
KR102212975B1 KR1020157028486A KR20157028486A KR102212975B1 KR 102212975 B1 KR102212975 B1 KR 102212975B1 KR 1020157028486 A KR1020157028486 A KR 1020157028486A KR 20157028486 A KR20157028486 A KR 20157028486A KR 102212975 B1 KR102212975 B1 KR 102212975B1
Authority
KR
South Korea
Prior art keywords
ethyl
compound
hydroxyacetamide
oxadiazol
hydroxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157028486A
Other languages
English (en)
Korean (ko)
Other versions
KR20150128947A (ko
Inventor
마르틴 볼리
시릴 레스콥
올리퍼 나일러
베아트 슈타이너
Original Assignee
이도르시아 파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이도르시아 파마슈티컬스 리미티드 filed Critical 이도르시아 파마슈티컬스 리미티드
Publication of KR20150128947A publication Critical patent/KR20150128947A/ko
Application granted granted Critical
Publication of KR102212975B1 publication Critical patent/KR102212975B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020157028486A 2013-03-15 2014-03-14 피리딘-4-일 유도체 Expired - Fee Related KR102212975B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159482 2013-03-15
EP13159482.2 2013-03-15
PCT/IB2014/059794 WO2014141171A1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Publications (2)

Publication Number Publication Date
KR20150128947A KR20150128947A (ko) 2015-11-18
KR102212975B1 true KR102212975B1 (ko) 2021-02-05

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157028486A Expired - Fee Related KR102212975B1 (ko) 2013-03-15 2014-03-14 피리딘-4-일 유도체

Country Status (33)

Country Link
US (1) US9617250B2 (enExample)
EP (1) EP2970236B1 (enExample)
JP (1) JP6387361B2 (enExample)
KR (1) KR102212975B1 (enExample)
CN (1) CN105189487B (enExample)
AR (1) AR095523A1 (enExample)
AU (1) AU2014229217B2 (enExample)
BR (1) BR112015023161B1 (enExample)
CA (1) CA2900910C (enExample)
CL (1) CL2015002620A1 (enExample)
CY (1) CY1119619T1 (enExample)
DK (1) DK2970236T3 (enExample)
EA (1) EA029309B1 (enExample)
ES (1) ES2649475T3 (enExample)
HR (1) HRP20171763T1 (enExample)
HU (1) HUE035154T2 (enExample)
IL (1) IL241363B (enExample)
LT (1) LT2970236T (enExample)
MA (1) MA38482B1 (enExample)
MX (1) MX363545B (enExample)
MY (1) MY173573A (enExample)
NO (1) NO2970236T3 (enExample)
NZ (1) NZ713080A (enExample)
PH (1) PH12015502118B1 (enExample)
PL (1) PL2970236T3 (enExample)
PT (1) PT2970236T (enExample)
SA (1) SA515361104B1 (enExample)
SG (1) SG11201507227UA (enExample)
SI (1) SI2970236T1 (enExample)
TW (1) TWI623534B (enExample)
UA (1) UA115357C2 (enExample)
WO (1) WO2014141171A1 (enExample)
ZA (1) ZA201507657B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029370A1 (en) 2006-09-08 2008-03-13 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
EP1070080A4 (en) 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
AU2007292993B2 (en) * 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
MX2009002915A (es) 2006-09-21 2009-03-31 Actelion Pharmaceuticals Ltd Derivados de fenilo y su uso como inmunomoduladores.
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
PT2195311E (pt) 2007-08-17 2011-05-25 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores do receptor s1p1/edg1
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
CA2700917A1 (en) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
JP2011513385A (ja) 2008-03-06 2011-04-28 アクテリオン ファーマシューティカルズ リミテッド 新規なピリミジン−ピリジン誘導体
JP5411877B2 (ja) 2008-03-06 2014-02-12 アクテリオン ファーマシューティカルズ リミテッド ピリジン化合物
CN102015695B (zh) 2008-03-07 2014-08-27 埃科特莱茵药品有限公司 吡啶-2-基衍生物
JP5481395B2 (ja) 2008-03-07 2014-04-23 アクテリオン ファーマシューティカルズ リミテッド 新規なアミノメチルベンゼン誘導体
AU2009258242B2 (en) * 2008-05-14 2015-07-16 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
EP2403849B1 (en) 2009-03-03 2014-07-16 Merck Serono S.A. Oxazole pyridine derivatives useful as S1P1 receptor agonists
SI2454255T1 (sl) 2009-07-16 2014-01-31 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot agonisti s1p1/edg1
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
KR101869120B1 (ko) 2011-01-19 2018-06-19 이도르시아 파마슈티컬스 리미티드 2-메톡시-피리딘-4-일 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029370A1 (en) 2006-09-08 2008-03-13 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents

Also Published As

Publication number Publication date
TW201443044A (zh) 2014-11-16
ZA201507657B (en) 2022-08-31
BR112015023161A2 (pt) 2017-07-18
BR112015023161B1 (pt) 2022-11-16
CL2015002620A1 (es) 2016-03-18
JP6387361B2 (ja) 2018-09-05
UA115357C2 (uk) 2017-10-25
WO2014141171A1 (en) 2014-09-18
IL241363B (en) 2018-11-29
EA029309B1 (ru) 2018-03-30
LT2970236T (lt) 2017-11-10
AU2014229217A1 (en) 2015-11-05
SI2970236T1 (sl) 2017-11-30
EP2970236A1 (en) 2016-01-20
PH12015502118A1 (en) 2016-01-25
EA201500931A1 (ru) 2016-03-31
TWI623534B (zh) 2018-05-11
HRP20171763T1 (hr) 2017-12-29
US20160031866A1 (en) 2016-02-04
AR095523A1 (es) 2015-10-21
MA38482A1 (fr) 2017-12-29
PT2970236T (pt) 2017-11-30
DK2970236T3 (en) 2017-10-16
HUE035154T2 (en) 2018-05-02
PL2970236T3 (pl) 2018-01-31
MA38482B1 (fr) 2018-11-30
PH12015502118B1 (en) 2016-01-25
AU2014229217B2 (en) 2017-12-14
CA2900910A1 (en) 2014-09-18
EP2970236B1 (en) 2017-08-30
CA2900910C (en) 2021-03-30
NO2970236T3 (enExample) 2018-01-27
CN105189487A (zh) 2015-12-23
IL241363A0 (en) 2015-11-30
CN105189487B (zh) 2017-12-26
SG11201507227UA (en) 2015-10-29
MX2015012293A (es) 2015-12-16
NZ713080A (en) 2020-06-26
ES2649475T3 (es) 2018-01-12
HK1220454A1 (en) 2017-05-05
SA515361104B1 (ar) 2016-06-28
US9617250B2 (en) 2017-04-11
BR112015023161A8 (pt) 2021-06-22
JP2016512227A (ja) 2016-04-25
CY1119619T1 (el) 2018-04-04
KR20150128947A (ko) 2015-11-18
MX363545B (es) 2019-03-27
MY173573A (en) 2020-02-04

Similar Documents

Publication Publication Date Title
KR102212975B1 (ko) 피리딘-4-일 유도체
JP5036923B1 (ja) ピリジン−4−イル誘導体
EP2069318B1 (en) Phenyl derivatives and their use as immunomodulators
JP5411877B2 (ja) ピリジン化合物
WO2005123677A1 (en) 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
JP2011513385A (ja) 新規なピリミジン−ピリジン誘導体
KR20140014128A (ko) 2-메톡시-피리딘-4-일 유도체
HK1220454B (en) Pyridin-4-yl derivatives
HK1170479B (en) Pyridin-4-yl derivatives as s1p1/edg1 agonists
HK1134294B (en) Thiophene derivatives as s1p1/edg1 receptor agonists
HK1134294A1 (en) Thiophene derivatives as s1p1/edg1 receptor agonists

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240202

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240202